Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
1995-12-14
2008-03-18
Parkin, J. S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S205100, C424S209100, C536S023720
Reexamination Certificate
active
07344722
ABSTRACT:
The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously published sequences for cold-adapted A/Ann Arbor/6/60 genes. The cold-adapted live influenza virus of the present invention can be reassorted with a variety of epidemic wild type influenza viruses and used to produce vaccines to prophylactically and therapeutically treat influenza.
REFERENCES:
patent: 5166057 (1992-11-01), Palese et al.
Maassab H et al., Evaluation of a cold-recombinant influenza virus vaccine in ferrets; J. Infect. Dis. 146(6):780-790, Dec. 1982.
Cox N et al., Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60; Virol. 167:554-567, 1988.
Cox, N. J., et al., 1988, “Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60(H2N2)”, Virol. 167:554-567.
Maassab, H. F., et al., 1982, “Evaluation of cold-recombinant influenza virus vaccine in ferrets”, J. Infect. Dis. 146(6):780-790.
Alexandrova, G.J. et al., “Obtaining of an additionally attenuated vaccinating cryophil influenza strain”Rev. Roum. D'Inframicrobiol. (1965) 2:179-189.
Schäfer, J.R. et al., “Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir”Virol. (1993) 194:781-788.
Chen, E.Y. et al., “Supercoil sequencing: A fast and simple method for sequencing plasmid DNA”DNA(1985) 4(2):165-170.
Edwards, K.M. et al., “A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease” (1993).
Chanock, R.M. et al., “Prospects for stabilization of attenuation”The Molecular Virology and Epidemiology of Influenza(1984) C.H. Stuart-Harris et al., eds., Academic Press, New York, pp. 237-256.
Ghendon, Y., “Vaccination against influenza viruses: Current status”Viral Vaccines(1990) Wiley-Liss, New York. pp. 159-201.
Herlocher, M.L. et al., “Molecular and biological changes in the cold-adapted “master strain” A/AA/6/60 (H2N2) influenza virus”Proc. Natl. Acad. Sci.USA(1993) 90:6032-6036.
Luytjes, W. et al., “Amplification, expression, and packaging of a foreign gene by influenza virus”Cell(1989) 59:1107-1113.
Macadam, A.J. et al., “Correlation of RNA secondary structure and attenuation of sabin vaccine strains of poliovirus in tissue culture”Virology(1992) 198:415-422.
Feng, S. et al., “HIV-1tat trans-activation requires the loop sequence withtar” Nature1988) 334:165-167.
Subbarao, E.K. et al., “Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bering a site-specific temperature-sensitive and attenuating mutation”J. Virol. (1993) 67(12):7223-7228.
Herlocher, M.L. et al., “Origin oftsphenotype expression of cold-adapted influenza virus A/AA/6/60”Genetics and Pathogenicity of negative strand viruses(1989) D. Kolakofsky et al., eds., Elsevier, New York, pp. 387-401.
Alexandrova, G. I., et al., “Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates” (1990)Vaccine8:61-64.
Belshe, R.B., et al. “Immunization of Infants and Young Children with Live Attenuated Trivalent Cold-Recombinant Influenza A H1N1, and B Vaccine” (1992)J. Infectious Diseases165:727-732.
Clavo, A.C., et al., “A persistent infection in MDCK cells by an influenza type B virus” (1993)Virus Research29:21-31.
Clements, M. L., et al., “Evaluation of Bovine, Cold-Adapted Human, and Wild-Type Human Parainfluenza Type 3 Viruses in Adult Volunteers and in Chimpanzees” (1991)J. of Clinical Microbiology29:1175-1182.
Clements, M. L., et al. “Evaluation of the Infectivity, Immunogenicity, and Efficacy of Live Cold-Adapted Influenza B/Ann Arbor/1/86 Reassortant Virus Vaccine in Adult Volunteers” (1990)J. of Infectious Diseases161:869-877.
Edwards, K.M., et al., “Safety and Immunogenicity of Live Attenuated Cold-Adapted Influenza B/Ann Arbor/1/86 Reassortant Virus Vaccine in Infants and Children” (1991)J. of Infectious Diseases163:740-745.
Gorse, G.J., et al., “Superiority of Live Attenuated compared with Inactivated Influenza A Virus Vaccines in Older, Chronically Ill Adults” (1991)Chest100:977-984.
Karron, R.A., et al., “A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine Is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and Children” (1995)J. of Infections Diseases171:1107-1114.
Maassab, H.F., et al., “Cold-Adapted Influenza Viruses for Use as Live Vaccines for Man” (1990)Viral Vaccines203-242.
Majde, J.A., et al., “Detection of toxic viral-associated double-stranded RNA (dsRNA) in influenza-infected lung” (1991)Microbial Pathogenesis10:105-115.
Sequential Analysis of the V3 Loup in HIV-1 From A Pediatric Population.
Massey J., et al., Abstract from General Mtg. “Genetic Variability in the HIV-1 Principle Neutralizing Domain from North American and African Isolates” (1993).
Powers, D.C., et al., “In Elderly Persons Live Attenuated Influenza A Virus Vaccines So Not Offer an Advantage over Inactivated Virus Vaccine in Inducing Serum or Secretory Antibodies of Local Immunologic Memory” (1991)J. of Clinical Microbiology29:498-505.
Riser, B.L., et al., “Differential Interaction of virulent and Attenuated Influenza Virus Strains with Ferret Alveolar Macrophages: Possible Role in Pathogenicity” (1990)J. of Infectious Diseases161:699-705.
Shaw, M.W., et al., “New Aspects of Influenza Viruses” (1992)J. of Clinical Microbiology5:74-92.
Snyder, M.H., et al., “A 36 nucleotide deletion mutation in the coding region of the NS1 gene of an influenza A virus RNA segment 8 specifies a temperature-dependent host range phenotype” (1990)Virus Research15:69-84.
Snyder, M.H., et al., “Attenuation and Phenotypic Stability of Influenza B/Texas/1/84 Cold-Adapted Reassortant Virus: Studies in Hamsters and Chimpanzees” (1989)J. of Infectious Diseases4:604-610.
Steinhoff et al. (1992) “Cold-Adapted Live Attenuated Influenza Virus Vaccine is Safe and Immunogenic in 2-5 Month Old Infants” Research Paper, Mtg of Am. Ped. Society, Ped. Res. 31(2) 179A.
Treanor, J.J., et al., “Protective Efficacy of Combined Live Intranasal and Inactivated Influenza A Virus Vaccines in the Elderly” (1992)Annals of Internal Medicine117:625-633.
Treanor, J.J., et al., “Evaluation of Live Attenuated Cold-Adapted Influenza B/Yamagata/16/88 Reassortant Virus Vaccine in Healthy Adults” (1993)J. of Infectious Diseases168:455-459.
van Wyke, K.L., et al., “Antibody Responses of Humans and Nonhuman Primates to Individual Antigenic Sites of the Hemagglutinin-Neuraminidase and Fusion Glycoproteins after Primary Infection or Reinfection with Parainfluenza Type 3 Virus” (1990)J. of Virology64:3833-3843.
van Wyke, K.L., et al., “Attenuation of Bovine Parainfluenza Virus Type 3 in Nonhuman Primates and Its Ability to Confer Immunity to Human Parainfluenza Virus Type 3 Challenge” (1988)J. of Infectious Diseases157:655-662.
Dowling-Whitaker, P., et al., “The Genes Associated with Trans-dominance of the Influenza A Cold-Adapted Live Virus Vaccine” (1901)Virology180:81-87.
Dowling-Whitaker, P., et al., “Dominant-Negative Mutants as Antiviral Agents: Simultaneous Infection with the Cold-Adapted Live-Virus Vaccine for Influenza A Protects Ferrets from Disease Produced by Wild-Type Influenza A” (1991)J. of Infectious Diseases164:1200-1202.
Yamane N., et al., (1992
Herlocher Martha Louise
Maassab Hunein F.
Bingham & McCutchen LLP
McGowan Malcolm K.
Parkin J. S.
The Regents of the University of Michigan
LandOfFree
Cold-adapted influenza virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cold-adapted influenza virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cold-adapted influenza virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3980234